Archives
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-10
Gu et al. show that CDK4/6 blockade can restrain pancreatic tumor-cell proliferation while unintentionally enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies GSK3β-mediated Wnt/β-catenin activation as a mechanistic link and demonstrates that BET inhibition with JQ1 can restore antitumor activity in combination with palbociclib.
-
FLOT1–FOSL2–EphA2 Axis in Alzheimer’s Neuroinflammation
2026-09-09
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 signaling axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model. Its combination of molecular interaction assays, transcriptional analysis, and behavioral testing connects a defined regulatory mechanism with reduced neuroinflammation and improved spatial memory after FLOT1 disruption.
-
LGK-974: A Practical PORCN Inhibitor Workflow
2026-09-09
Build cleaner Wnt-dependency experiments with LGK-974, from sub-nanomolar pathway engagement to pancreatic cancer model selection. This guide combines target-engagement readouts, phenotype controls, and troubleshooting strategies for Wnt-driven cancer therapy research.
-
FK866 (APO866): NAMPT Assay Workflows
2026-09-08
Build mechanism-focused NAD depletion assays with FK866 (APO866), from AML viability profiling to vascular smooth muscle cell studies. The workflow combines metabolic, mitochondrial, DNA-damage, and senescence readouts to distinguish target engagement from nonspecific toxicity.
-
CHIR-99021: Engineering Better Neuronal Assays
2026-09-07
CHIR-99021 (CT99021) is more than a pluripotency reagent: it can help researchers reason about state control during stem-cell-derived neuronal assay development. This article connects selective GSK-3 inhibition with the validated human sensory-neuron model for HSV-1 latency and explains practical controls, readouts, and limitations.
-
(R)-MG132 for Proteasome Control Assays
2026-09-07
Use (R)-MG132 as a stereochemically matched negative control to test whether cellular phenotypes truly depend on proteasome inhibition rather than solvent, peptide-aldehyde, or nonspecific stress. Its value is especially clear when studying HNRNPU stability, PHGDH expression, and serine metabolism in cervical cancer models.
-
Annexin V-FITC/7-AAD Apoptosis Kit Workflow
2026-09-05
Build a rapid two-color workflow that separates viable, early apoptotic, late apoptotic, and membrane-compromised cells in drug-response studies. This guide translates a corynoline osteosarcoma study into practical assay design, controls, gating, and troubleshooting for flow cytometry or fluorescence microscopy.
-
Aβ42: From Plaque Burden to Cell-State Signaling
2026-09-04
A translational framework for using Amyloid β-Peptide (1-42) to connect peptide assembly with neuronal toxicity, ion-channel dysfunction, and microglial phagocytosis in Alzheimer’s disease research.
-
XAV-939 Workflows for Wnt Pathway Research
2026-09-04
XAV-939 and NVP-XAV939 provide a practical way to suppress Wnt/β-catenin signaling through tankyrase inhibition, with applications spanning cancer research, synovial inflammation, fibrosis, and osteogenic differentiation. This guide translates published pathway experiments into reproducible setup, dosing, readout, and troubleshooting strategies.
-
T7 RNA Polymerase for RNA Assay Workflows
2026-09-04
T7 RNA Polymerase converts promoter-bearing DNA into defined RNA for translation, RNA stability, RNAi, structural, and hybridization assays. This workflow-focused guide explains how to pair a recombinant enzyme expressed in E. coli with linearized plasmids or PCR templates, while using the DDX21–NAT10 colorectal cancer study to refine RNA assay design.
-
IR-820: Designing Better NIR Imaging Assays
2026-09-03
IR-820, also called New Indocyanine Green, supports quantitative near-infrared fluorescence imaging of vascular and tumor biology. This guide explains how to translate insights from indocyanine green nanomedicine research into better assay design without confusing imaging evidence with therapeutic claims.
-
SAM as a Mechanistic Lever in Liver Fibrosis
2026-09-02
S-Adenosylmethionine is more than a methyl donor: it is a tractable metabolic perturbation for testing how methionine-cycle disruption shapes autophagy, hepatic stellate cell fate, and translational assay design.
-
HLY78: Reliable Wnt/β-Catenin Assay Design
2026-09-02
Learn how HLY78, SKU C5433, can support controlled Wnt/β-catenin pathway experiments without confusing pathway activation with cell viability. This scenario-based guide covers assay design, solvent control, protocol optimization, interpretation, and practical reagent selection.
-
Wnt Agonist 1 (BML-284): Mechanism & Research Use
2026-09-01
Wnt agonist 1, also called BML-284, is a small-molecule activator of β-catenin-dependent TCF transcription. Its reported activity and Xenopus phenotype support applications in Wnt pathway cellular differentiation research, developmental biology research, and mechanistic studies of Wnt-linked chemoresistance.
-
Hexetidine (NSC-17764) for Reliable Assays
2026-09-01
This scenario-driven guide explains how Hexetidine (NSC-17764), SKU BA1327, can be incorporated into antimicrobial, biofilm, and cell-assay workflows without confusing microbial inhibition with mammalian cytotoxicity. It provides evidence-linked concentration benchmarks, compatibility precautions, interpretation guidance, and practical product-selection criteria.